Podcasts about inhibition

In today's episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about prostate cancer management and the use of androgen receptor (AR)–directed therapies. Dr Shore is the medical director for the Carolina Urologic Research Center in Myrtle Beach, South Carolina.  In our exclusive interview, we sat down with Dr Shore during the 2025 Bridging the Gaps in Prostate Cancer meeting to discuss the importance of multidisciplinary meetings to address unmet needs for patients with prostate cancer, the need for treatment strategies that improve upon the activity of current standards of care in this disease, the evolving roles of neoadjuvant and adjuvant therapies, and the significance of biomarkers and imaging. He also highlighted treatment advances that have been achieved with AR-directed agents, such as apalutamide (Erleada) and darolutamide (Nubeqa), along with considerations for the optimal intensification and de-intensification of these agents to balance efficacy and quality of life. 

This interview with JACC: Associate Editor Neha J. Pagidipati, MD, FACC, and author Kausik Ray, MD, FACC, reviews Dr. Ray's phase one study on solbinsiran, an siRNA therapy targeting ANGPTL3 to reduce triglycerides and cardiovascular risk. Dr. Ray explains the study's findings, including significant reductions in triglycerides, ApoB, and LDL, with a favorable safety profile. The conversation also touches on the broader landscape of ANGPTL3 inhibitors, the implications of HDL reduction, and the anticipation of phase two results to be presented at ACC 2025.

Appendiceal neoplasms present with peritoneal carcinomatosis and despite aggressive CRS/HIPEC, often recur and are chemotherapy resistant. In this Colorectal DSWG SSO sponsored podcast episode, we discuss an overview of the recent publication of "Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis with GNAS Mutations" by Dr. Lowy's research lab at UCSD. The authors treated 16 patients in this Phase 2 study of oral Palbociclib in recurrent appendiceal adenocarcinoma patients and identified excellent treatment and long-term response with 13/16 of patients treated having reduction in CEA and excellent survival (median FU of 17.6 months, OS not reached). Dr Lowy provides informative background, study details and discusses next steps for this novel treatment approach. A link to the paper in question is https://pubmed.ncbi.nlm.nih.gov/39413348/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Michael Lizardo, MS, PhD, a staff scientist in the Poul Sorensen laboratory at BC Cancer Agency, joins us on OsteoBites to discuss how the pharmacologic inhibition of EIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis.Dr. Lizardo shares his lab's recent findings in Clinical Cancer Research on how targeting the dysregulated mRNA translation factor eukaryotic initiation factor 4A (EIF4A), via pharmacological inhibitors, prevents the protein synthesis of nuclear factor erythroid 2–related factor 2 (NRF2), which is a cytoprotective protein metastatic OS cells require to successfully colonize the harsh microenvironment of the lung. He also discusses how the EIF4A1 inhibitor, CR-1-31B, and a related clinical-grade compound (Zotatifin) prevent OS cell adaptation to oxidative stress (a major stressor in the lung) in 2D and 3D cell culture models, as well as ex vivo lung organotypic cultures. Moreover, he discusses how drug treatment can inhibit lung metastasis and prolong the survival of animal subjects in pre-clinical mouse models of metastatic OS.

Drs. Katherine Talcott and Akshay Thomas join to discuss the March 2025 edition of Retinal Physician focusing on dry age-related macular degeneration, including photobiomodulation, complement inhibition, and deep learning for imaging.Relevant Financial Disclosures: Dr. Sridhar has consulted for Apellis.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.

Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.

In this episode, we discuss the intricate relationship between Autism and speech & language, emphasizing the critical role of neuroscience in understanding these dynamics. The discussion begins by highlighting how speech and language are foundational to human evolution and social interaction, yet pose unique challenges for individuals with Autism. The episode explores the brain's key regions involved in these processes, such as Broca's area, responsible for speech production, and Wernicke's area, crucial for language comprehension. These regions are connected by the arcuate fasciculus, a white matter tract essential for language processing, repetition, and verbal working memory.The podcast also examines how the basal ganglia, particularly the dorsal striatum, contributes to speech fluency and motor sequencing, including the articulation of words. By integrating neuroscience, we gain insight into the biological underpinnings of communication difficulties in Autism, such as delays in language processing and the phenomenon of "choppy" speech, which are linked to less coherent organization within these neural pathways.The episode further unpacks the concept of neuroplasticity and its implications for Autism, emphasizing the brain's ability to adapt through practice and repetition, leading to habits. The discussion also touches on the role of the dorsal medial striatum in goal-directed learning and the dorsal lateral striatum in habit formation, illustrating how these areas influence speech and language acquisition. Additionally, the podcast explores the phenomenon of echolalia, often observed in Autistic individuals, as a potential mechanism for processing delays or as a result of cyclical loops in the basal ganglia.The interplay of neurotransmitters like GABA and glutamate is highlighted, explaining the excitation-inhibition imbalance often seen in Autism, which affects sensory processing and communication. By framing these challenges through the lens of neuroscience, the episode underscores the complexity of social interaction for Autistic individuals and the importance of understanding the brain's predictive and adaptive mechanisms to better support their needs.00:00 - Introduction to Autism and Speech02:02 - The Speaker-Receiver Dynamic in Autism04:02 - Visual Thinking and Processing in Autism06:18 - Neuroscience of Speech and Language08:20 - The Role of the Basal Ganglia in Speech10:39 - Echolalia and Sensory Processing Delays16:53 - Neuroplasticity and Speech Therapy17:22 - Reflexes, Inhibition, and GABA in Speech and Autism20:02 - Basal Ganglia Circuits, Motivation, and Echolalia from getting "stuck"24:03 - Language Acquisition and Rule-Setting in Autism27:47 - Energy, Learning, and Social Challenges30:15 - Contingency-Based Learning and Outcomes31:46 - Reviews/Ratings and Contact infoX: https://x.com/rps47586Hopp: https://www.hopp.bio/fromthespectrumYT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

We're back, after a brief hiatus! Today we talk about duration of therapy for bacteremia, Factor XI inhibition for atrial fibrillation, whether to stop ACEi or ARB before elective surgery, and whether GLP-1 agonists are beneficial in heart failure with preserved ejection fraction. Go to minute 7:30 to skip the banter. 7 vs 14 Days of Antibiotics for Bacteremia (BALANCE)Abelacimab vs Rivaroxaban for Atrial Fibrillation (AZALEA-TIMI-71)Asenduxian vs Apixaban for Atrial Fibrillation (OCEANIC-AF)ACEi or ARB Discontinuation Before Surgery (STOP or NOT)Tirzepatide for HFpEF and Obesity (SUMMIT)Music from Uppbeat (free for Creators!):https://uppbeat.io/t/soundroll/dopeLicense code: NP8HLP5WKGKXFW2R

Watch our panel of experts and get up to speed on hypertrophic cardiomyopathy (HCM) through a series of quickfire questions and teaching points. Credit available for this activity expires: 01/31/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/new-paradigms-hypertrophic-cardiomyopathy-care-gameshow-2025a10002f4?ecd=bdc_podcast_libsyn_mscpedu

CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/neonatal-fcrn-inhibition-a-new-pathway-for-addressing-the-alloimmune-disorders-of-pregnancy/32281/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable advanced or metastatic melanoma. Results from the study were reported at the European Society for Medical Oncology (ESMO) 2024 Annual Congress, held in Barcelona, Spain.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

In this podcast, expert clinicians will review the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in reducing low-density lipoprotein cholesterol (LDL-C) and reducing cardiovascular risk. https://healio.com/cme/mededtalks/cardiology/20250102/4-lipid-legends-with-your-host-dr-ronald-codario-featuring-dr-peter-toth-pcsk9-inhibition

Can you reduce activation of one muscle, by increasing activation of another? Find out in this episode.Resources mentioned in the episode: Read the paper cited in this episode here. Connect with me on Instagram: @the_raphaelbenderDownload a free course guide:Pilates CertificationVisualized AnatomyThis podcast uses the following third-party services for analysis: AdBarker - https://adbarker.com/privacy

A clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYNOTE-A18 study of immunotherapy together with concurrent chemoradiotherapy among 1,060 patients who had newly diagnosed, previously untreated high-risk locally advanced cervical cancer. A multinational team of researchers, led from Italy, reported findings at the ESMO Congress 2024. There was a statistically significant increase in 36-month overall survival in patients treated with pembrolizumab, in addition to chemoradiotherapy, in comparison to those in the control group who received standard chemoradiation alone.

Drs. Safa Rahmani and Sarwar Zahid join the podcast to preview the January 2025 edition of Retinal Physician, found online at http://www.retinalphysician.com.Relevant Financial Disclosures: Dr. Sridhar has consulted for Genentech and Regeneron.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this episode of the Kids with Big Emotions podcast, we dive into the world of impulsivity and explore strategies to help kids pause, reflect, and make thoughtful decisions. If your child often acts without thinking, struggles to stop themselves, or faces social and emotional challenges due to impulsivity, this episode is for you.Learn why impulsivity happens, the foundational skills kids need to develop inhibition, and practical steps you can take to support them in creating that all-important pause before they act.Key Takeaways:What is Inhibition? Inhibition is the ability to pause and think before acting on impulse. It helps kids (and adults!) avoid blurting out, interrupting, or reacting emotionally without considering the consequences.What Impacts Impulsivity? Impulsivity can stem from an underdeveloped executive functioning system. Kids need attention, perception, and working memory to stop and think before acting.Why "Just Stop!" Doesn't Work: Simply telling kids to stop isn't enough. They need help learning how to pause, reflect, and process the situation.Practical Strategies: Teaching kids to use alarms, create plans, and break tasks into steps can build their inhibition skills over time.Understand the Whiteboard Effect: When kids' brains are overloaded with distractions, emotions, and external stimuli, their ability to pause is diminished. Reducing this "whiteboard clutter" is key to helping them focus.Episode Highlights:[00:00:00] Introduction: Recognizing impulsivity in kids and how it shows up in daily life (e.g., blurting out, hitting, or struggling to wait their turn).[00:02:00] What is Inhibition? The ability to pause and think before acting—and why it's crucial for social and emotional development.[00:04:00] The Building Blocks of Inhibition: How skills like attention, perception, and working memory play a role in self-control.[00:08:00] The Impact of Overload: Why kids struggle more with impulsivity when their executive functioning system is taxed (e.g., after a late night or an overstimulating event).[00:10:00] The Whiteboard Effect: How distractions, emotions, and screens overload a child's mental "whiteboard," making it harder for them to pause and think.[00:16:00] Why Screens Make Impulsivity Worse: The high working memory demands of screens and how they pull kids' attention away from what they should be doing.[00:18:00] Creating Space to Pause: How to teach kids to stop and reflect before acting, and why this skill builds healthier relationships and better emotional regulation.[00:22:00] Strategies That Work: Practical tips for helping kids navigate impulsivity, including alarms, breathing exercises, and step-by-step plans.[00:30:00] The Power of Individualized Plans: Why each child's inhibition strategies need to match their unique executive functioning profile.[00:34:00] Long-Term Growth: Understanding how inhibition develops over time and why challenges may resurface during different life stages.Resources Mentioned:Inhibition Intake Form: A detailed self-assessment tool to help parents identify their child's challenges and strengths in inhibition. https://docs.google.com/document/d/1hZqpIgPgFXB_V8_1NGsiClJ6O2GAHb5jXdJNzSxg-yY/edit?usp=sharing Support Circle Membership:...

Yes, Dot Hacker's lead vocalist Josh Klinghoffer played guitar with Red Hot Chili Peppers for 10 years - trigger warning for some - but before forming in 2008 all four members were already established musicians, recording and touring with an impressive list of respected artists including: Beck, Gnarls Barkley, PJ Harvey, The Butthole Surfers and Broken Bells amongst many others. This week's guest, musician/audio engineer Layla Moheimani, fell instantly under the spell of the band and their lush, architectural-yet-still-rocking debut release 'Inhibition'.  Songs discussed in this episode: What Red Hot Chili Peppers Sound Like To People Who Don't Like Red Hot Chili Peppers - There I Ruined It; Unreachable - John Frusciante; Billie Holiday - Warpaint; The Afterglow - John Frusciante & Josh Klinghoffer; Going On - Gnarls Barkley; Biblical Violence - Hella; Overpour - E V Kain; Order/Disorder, Idleidolidyl, Eye Opener, Discotheque, Be Leaving, The Earth Beneath, Inhibition - Dot Hacker; Mystic Lady - T-Rex; The Wit of the Staircase - Dot Hacker; Dreams of a Samurai - Red Hot Chili Peppers; Quotes, Puncture - Dot Hacker; Fade Into You (Mazzy Star cover) - Layla Joon

What causes the “red wine headache”? Is it sulfites? A histamine reaction? Andrew Waterhouse, Professor Emeritus of Enology in the Department of Viticulture and Enology at UC Davis and Apramita Devi, Postdoctoral Scholar in the Department of Viticulture and Enology at UC Davis have identified a flavanol that can interfere with the metabolism of alcohol. That flavanol is quercetin, a natural product made in grape skins in response to sunlight. It is a natural sunscreen produced to protect the fruit from ultraviolet light. This conversation covers why quercetin may be more prevalent in high end wines, how skin contact during wine production impacts quercetin levels, and why sulfites may play a role in “red wine headache”. Resources:         74: The Spirit of Wine Andrew Waterhouse Andrew Waterhouse | Google Scholar Andrew Waterhouse | LinkedIn Apramita Devi | LinkedIn Apramita Devi |Google Scholar Inhibition of ALDH2 by quercetin glucuronide suggests a new hypothesis to explain red wine headaches Why Do Some People Get Headaches From Drinking Red Wine?  Vineyard Team Programs: Juan Nevarez Memorial Scholarship - Donate SIP Certified – Show your care for the people and planet   Sustainable Ag Expo – The premiere winegrowing event of the year Sustainable Winegrowing On-Demand (Western SARE) – Learn at your own pace Vineyard Team – Become a Member Get More Subscribe wherever you listen so you never miss an episode on the latest science and research with the Sustainable Winegrowing Podcast. Since 1994, Vineyard Team has been your resource for workshops and field demonstrations, research, and events dedicated to the stewardship of our natural resources. Learn more at www.vineyardteam.org.   Transcript [00:00:00] Beth Vukmanic: What causes. The red wine headache? Is it sulfites or a histamine reaction? [00:00:10] Welcome to sustainable wine growing with the vineyard team. Where we bring you the latest in science and research for the wine industry. I'm Beth Vukmanic executive director. I've been your team. Since 1994, we've brought you the latest science-based practices, experts growers and wine industry tools through both infield and online education. So that you can grow your business. Please raise a glass. With us as we cheers to 30 years. [00:00:37] In today's podcast, Craig Macmillan, critical resource. Manager at Niner wine estates with long time sip certified. Vineyard and the first ever sip certified winery. Speaks with two university of California Davis researchers. Andrew Waterhouse. Professor emeritus of enology and the department. of, viticulture and enology. And. Oprah meta Debbie. Post-doctoral scholar and the department of viticulture and enology. [00:01:04] They have identified a flavonol that can interfere. With the metabolism of alcohol. And that flavonol is called quercetin. A natural product made in the grape skins in response. To sunlight. It's a natural sunscreen produced to protect. The fruit from ultraviolet light. This conversation covers. Why quercetin may be more prevalent in high end wines. How. Skin contact during wine production impacts quercetin levels. And why sulfites may still play a role in that red wine headache. [00:01:36] Want to be more connected with the viticulture industry. But don't know where to start become a vineyard team member. Get access. to the latest science-based practices, experts, growers, and wine industry. The tools. Through both infield and online education so that you. You can grow your business. Visit vineyard team.org. And choose grower or business to join the community today. [00:01:57] Now let's listen. in. [00:02:01] Craig Macmillan: Our guests today are Andrew Waterhouse, Professor Emeritus in Enology in the Department of Viticulture Davis, and also Aparmita Devi. She is a postdoctoral scholar, also in the Department of Viticulture & Enology Davis. Thank you both for being here. [00:02:17] Andrew Waterhouse: Oh, we're glad to be here. [00:02:19] Craig Macmillan: Today we're going to talk about a really interesting topic. It's the role of quercetin , in wine headaches. The two of you recently co authored a paper on this one particular mechanism that might cause some people to get a headache after drinking even a small amount of red wine. But before we get into that, I want to ask you, how did you get interested in this topic? [00:02:37] Andrew Waterhouse: Well I've been talking to Steve Mathiasson. He's a Napa winemaker for actually quite a while, some years back. He suffers from headaches when he drinks certain wines. And we were chatting about possible mechanisms, and we even did a study many years ago with another postdoc in my lab to investigate a question we had or a theory we had, and that didn't pan out. But more recently we were chatting again, and I got interested in the topic again, and that's what got me interested, you know, just somebody knowledgeable who was suffering from headaches and. for listening. It was, it makes it more real and it's like, well, maybe we can figure something out. So that's what got us started. [00:03:17] Craig Macmillan: Apramita , how same for you. [00:03:19] Apramita Devi: Yeah. Same. Like I've been in touch with Andy and we have been talking about this project many years. So I was always interested because I come from biological science and metabolism and stuff I got interested after talking to Andy. [00:03:33] Craig Macmillan: Well, let's start with some basics. What is quercetin? [00:03:38] Andrew Waterhouse: Well, basically, it's a natural product made by grapes, but it's a very specific one. It's in the class of polyphenolic compounds, and it's in the class of flavonoids called flavonols. And what makes it interesting, I think, is that it is made By grapes, in the skin of the grape, and only in the skin of the grape, in response to sunlight. It's sometimes referred to as sunscreen for grapes. And it specifically absorbs UV light that would cause damage to, say, DNA and other macromolecules. So it's very clear that the grapes are producing this in order to protect themselves from ultraviolet light. [00:04:22] Craig Macmillan: Right. [00:04:22] Andrew Waterhouse: So the amount that's present in wine is highly dependent on the amount of sunlight the grapes experience. Not the vine, but the grapes themselves, And a friend of mine, Steve Price, was the first to note this. In a study way back in the 90s on Pinot Noir, he noted that there was more quercetin in sun exposed Pinot Noir grapes. And that observation has been confirmed many times now in different studies. where sun exposure is correlated with quercetin levels. [00:04:58] Craig Macmillan: and this is true just for red grapes as opposed to white grapes. [00:05:02] Andrew Waterhouse: Oh, no, no, there's more in white grapes. But when you make white wine, you throw away the skins. So there's no opportunity to get those materials into the wine. Now, an exception might be orange wine. But I don't know of any data on orange wine. [00:05:21] Craig Macmillan: Apramita , maybe you can talk about the metabolism part, the biology part. So when people consume alcohol, it's metabolized down certain pathways. Quercetin is also metabolized by the body into other forms? [00:05:33] Apramita Devi: Yeah, so the pathway for alcohol and quercetin are a bit different, but the location is liver, where it goes. So when people consume alcohol, it goes to the liver and then there are two enzymes which work on the alcohol. So the first enzyme is alcohol dehydrogenase, which convert it into alcohol into acetaldehyde. The acetaldehyde is the like the toxic metabolite in the body and it can have many side effects. That's why body has to get rid of it out of the liver system. So it has a second enzyme which is called the acetaldehyde dehydrogenase. So that convert acetaldehyde dehydrogenase into a non toxic component, which is acetate or acetic system. [00:06:24] So it comes out of the body. What happens when you consume quercetin along in the body, the quercetin also goes to the liver. Because quercetin adds too much quercetin as such is not good for the body and it has low bioavailability. So liver tag it in the form of quercetin glucuronide and then the body knows that it has to be flushed out of the system. So the interesting part is that when you consume alcohol and quercetin together, You are taking the both the metabolite acetaldehyde and quercetin gluconide in the same location inside the liver. And it gives the quercetin gluconide to interact with the acetaldehyde dehydrogenase enzyme. And that acetaldehyde dehydrogenase enzyme now cannot work efficiently. to convert the acetaldehyde into the acetate. So basically you are building up acetaldehyde in the body and it's not coming out of the system and you are seeing all those negative effects of the acetaldehyde in the form of flushing or headache or not. The other systems like what's like sweating. so we think that there is a correlation between these two pathways, which might be associated in red wine system. [00:07:47] Craig Macmillan: And how did you design your study? [00:07:51] Apramita Devi: The first when I talked to Andy, like he told me that he thinks that this system is because of inflammatory pathways and inflammation system. So he was kind of like, there is something in red wine, which is Triggering this kind of pathways or there is some system so, but we were not sure what exactly are those inflammatory system. [00:08:16] So we went back and saw some literature and we kind of find that there are some studies which told that quercitans inhibit the dehydrogenase enzymes and that what triggered us that okay alcohol is metabolized by these dehydrogenase enzymes. And wine also has these phenolics. So what kind of phenolics, other kinds of phenolics, or what types of phenolics can do this inhibition? [00:08:45] The method was basically in, was based on having different phenolics, which are present in red wines more compared to white wines, select them. And then just, we find this enzyme kits in the market to do this dehydrogenase. Inhibition tests like you put the test compound and it tells whether the enzyme is the inhibited or not. [00:09:09] So we just did that in a test tube system, like we added our phenolics with the enzyme, and we saw that which kind of phenolics are inhibiting this enzyme and screening them out. out of all. So while doing that, we screened different types of quercetin, like quercetin glucoside, quercetin galactosides, and other forms. [00:09:32] Then we also tested other phenolics. I can for all my rest in and other stuff. And we also choose quercetin gluconide because that is the metabolite which is circulating in the body. And then we kind of screen them based on the in the enzyme system and we see how much inhibition is happening there. [00:09:54] Andrew Waterhouse: Yeah. So what we did was a very basic test to experiment. We didn't test anything on people. [00:10:01] We basically tested to see which of these compounds could inhibit that enzyme because we knew that if that an enzyme could be inhibited the acetaldehyde would accumulate and you'd end up with people in that condition would end up with Flushing, headaches, as Aparmita said, all kinds of other symptoms. [00:10:20] Craig Macmillan: And this would vary by person. Different people may have a proclivity to produce more of certain enzymes than others. Is that true? [00:10:29] Andrew Waterhouse: We don't really have any information about that. That's going to take a lot of more work to test you know, the, the details here. For instance. Some people get red wine headaches and some don't, but we don't know whether, for instance, perhaps their enzymes are more inhibited by quercetin glucuronide, or maybe they're just more sensitive to acetaldehyde. [00:10:52] So that's going to take, you know, human studies where we measure a bunch of things. And try to figure out, try to sort through the, the details of how this impacts people individually. [00:11:04] Craig Macmillan: What would a study , with people, investigating this, what would the design be like? How would somebody go about doing that? [00:11:12] Andrew Waterhouse: Okay. So a human study. Could have a couple different possible designs. The one we'll probably use is we'll simply find two wines, two red wines, one that's low in quercetin and one that's high. And then those will be administered to people who get red wine headaches. We'll give it to them blind, they'll have to agree of course to participate in the study. [00:11:37] And then we'll see if their experience of headaches is related to the quantity of quercetin. Now, there's some other designs we could imagine using, which might be a little more straightforward, but we're not sure how relevant they would be or whether we could get approval to do this. So, for instance, one approach would be to find a red wine that's low in quercetin and then simply add it. [00:12:00] Now adding it is tricky for a number of technical reasons. Quercetin itself is very insoluble, so we would have to add what's called a glycoside of quercetin. So we'd have to get our hands on something that would dissolve, et cetera, et cetera. We're not sure we could get approval for that because we're adding a chemical to wine. [00:12:21] Now, the chemical would probably be classified as a supplement, and so it might be approvable, as it were. And then another very simple experiment, which we thought about a while ago, you can buy quercetin as a supplement in the market. It's readily available. [00:12:38] So, one possibility is to simply give our subjects a glass of vodka and give them pills that either contain quercetin or a placebo and see if there's a relationship between administration of quercetin and headaches. [00:12:54] Now the, the quercetin itself, as I mentioned, is very insoluble. So we may have to get these more bioavailable forms of quercetin for that experiment. [00:13:04] Craig Macmillan: That leads to a wine making question. So, if it's relatively insoluble is quercetin extracted from skins more in the alcohol phase at the end of fermentation? [00:13:11] Andrew Waterhouse: Yeah. It's, it's, it's extracted fairly quickly because it's in the skin, in the grapes, it's in the form of what are called glycosides. So these, Has the quercetin molecule with the sugar attached. That makes all those forms very soluble. [00:13:27] Craig Macmillan: Oh, okay. Okay. [00:13:29] Andrew Waterhouse: There's actually an occasional problem with certain red wines, most commonly Sangiovese, where after bottling the wine has had a large quantity of quercetin glucosides. And after bottling, they break down, the glycosides break down, releasing just a simple a glycone, quercetin, and you get this disgusting looking gooey brown precipitate in the bottle. [00:13:56] Craig Macmillan: ha [00:13:57] Andrew Waterhouse: Every few years I know the folks at ETS in Napa get somebody showing up with a bottle of Sangiovese that's got this. Disgusting sludge in it, and they can tell them without analyzing that. Yes, another case, of course, it's in precipitate in the bottom. [00:14:15] Craig Macmillan: Huh, that's interesting. I believe it was mentioned in the paper that , obviously different growing conditions are going to lead to different levels of quercetin and grapes based on how much sun exposure they have, etc. And that also different winemaking techniques would have an impact. [00:14:29] If consumers are looking for products if they know they have a headache issue Is it possible they could experiment with different product types? Products that were made with different production methods if they can find that out that might Impact their sensitivity or might impact how often it happens [00:14:46] Andrew Waterhouse: Yeah, it's a pity that. Consumers wouldn't have information on the level of quercetin. We would very much like to do a study along those lines, but we haven't been able to find any funding for that, just in case somebody wants to support that kind of work, we're happy to work with them. but anyway you know, it hasn't really been an issue for winemakers, so there isn't a lot of data out there. [00:15:08] There are a few studies that published amounts of quercetin, you know, in wines from different places, but the data is very, very limited and not really useful in providing consumers guidance. The one thing we can say is because, as I mentioned earlier, sun exposure is very important, in general if you look at a particular type of wine, a varietal, say Cabernet or Pinot Noir, that the grapes that are grown on very large vines, will have less sun exposure. [00:15:39] Essentially if you have a very highly productive vineyard making targeting an inexpensive line, you probably have much more shading of the fruit as a consequence of lower quercetin levels. Compared to a very high end vineyard, usually, the amount of sunlight is very tightly controlled, and one of the reasons for that is that there's very good data showing that wines that are high in quercetin have a better mouthfeel, better texture in the mouth. And it's not clear whether quercetin is directly responsible or whether it's a marker for something else that's produced under those conditions that leads to that. many years ago, we did a study looking at phenolics in Cabernet, and we observed that the very high end Cabernets that we tested were much higher in quercetin than the sort of average price type product. [00:16:35] And I think that that was true then. It's probably true now that, you know, a very good cabernet is, is made with very tight control of sun exposure. And there is a fair amount, of course, it can't be a complete sun exposure, or they probably get raisins by the end of the harvest, by the time you get to harvest, but there's a very deliberate management of sun exposure in high end wines. And it's for a reason to, get to higher quality product. [00:17:04] Craig Macmillan: Right, exactly! And, We know that the managed sun exposure, quercetin is a part of it but also it's connected to just total phenolics in general. Lots and lots of different compounds that are, you know, semi related. And I actually wanted to go back Aprametia you identified the quercetin glucuronide as being The highest in the ones that you tested, were there other things in that test and that assay that all were also stood out, maybe not as high as that, but really kind of stuck out as being different than the rest. [00:17:39] Apramita Devi: Actually, the quercetin gluconide was a standalone as a very high, like it's like 78%. The other things were around in that 30 percent range, so I'm not sure how significant was the impact of that, but there were quercetin glycosides forms, which were like around 30 percent inhibition of the enzyme, but [00:18:03] all others were very low. [00:18:04] Craig Macmillan: yeah, so it really stood out basically as it was head and shoulders above it. I would like to put this work into context a little bit. I, I work with the public quite a bit as part of my job and I have for years. And this topic comes up. All the time. This information definitely helps me my goal, when I talk to a consumer that has an issue with, wine headache or whatever it's not that I'm trying to sell them a product as much as it is. [00:18:29] They want to enjoy wine. They tell me this, they say, Oh, I love to have it. I just can't. Da da da. And then they'll say, it's like sulfites. And then I'll kind of explore that with them a little bit. Like, so can you eat dried fruit? Do you eat canned fruit? Do you have reactions to this or to that? Are you asthmatic? [00:18:48] Kind of sort that out and go, okay, I don't think maybe that's it. Maybe it's not. The other ones that I just learned about about 10 years ago was a biogenic amines, which made a lot of sense to me in terms of things like histamine reactions. What is your feeling about sulfites is contributing biogenic amines. [00:19:04] Maybe there's other things we haven't hit on, on this topic. What are your feelings about the, kind of the big picture of what potential for a diagnosing assist? [00:19:15] Andrew Waterhouse: Why don't you talk about amines [00:19:16] Craig Macmillan: Yes, please, [00:19:18] Apramita Devi: Biogenic amines like mostly the histamine and tyramine are the main ones people talk about whenever they come with this headache stuff. So I think because it's formed in the wine during the fermentation process, and there are these spec microbes which can convert the amino acids into this, biogenic amines the histamines are part of inflammatory reactions. People know that in biology and immunology. So it's very easy to be people connected that it might be a reason why people get headache. But what I always focus is like, there are far more other food products, for example, fermented meat products, which has far more higher amount of these biogenic amines. do people get headache if they have something similar with alcohol eating together with alcohol or something like that? But there is no mechanism told till now, they just tell that, oh, since it's histamine and it's related to this inflammatory reactions, it might be the cause. But there is no solid proof that it is the cause. [00:20:27] so I don't know whether it's there or it might be a pathway or not. [00:20:33] Craig Macmillan: One of the things that I find fascinating is how we evolve our, Hypotheses about things over time, and somebody has an hypothesis and they test it out, maybe they find something, maybe they don't, but then that kicks off this whole set of what I call naive science making up stories about why. [00:20:53] It's kind of a just so story. It's like, well, obviously then somebody comes along and checks it and says, Hey, wait a second. And we're no, or if this was true, then that would have to be true. And that's not true. You know, and that kind of thing and how we keep coming around to new ideas, which is what you folks have done, which I think is really, really cool. [00:21:10] Andrew Waterhouse: I was going to answer your question about sulfites. It's a really big question actually. Partly because sulfites have so much visibility and there's so much concern about it. I think sulfites themselves Have been studied pretty carefully there's one study where if they gave subjects a very high level of sulfites in wine, it was like very small, but statistically significant increase in headaches. [00:21:39] Or some adverse reaction, but other studies have shown no correlation. By the way, sulfites are antioxidants in case you hadn't heard that. So it seems very unlikely that sulfites by themselves are some sort of bad actor in this regard. Like you, I get these questions all the time. And what I heard so many times was. Oh, it's cheap wine. It gives me a headache. [00:22:06] Craig Macmillan: Yes. [00:22:07] Andrew Waterhouse: And have you heard [00:22:08] Craig Macmillan: I've heard that many times. And then on the opposite side of things, I've heard stuff like, Oh, I get headaches from American wine, but I don't get it from French wine. Or I always get headaches from European wines, but I never from California wine. So I'm trying to figure out, is there something going on? [00:22:26] Like, can you be allergic to burgundy? You know what I'm saying? Cause I mean, it could be, it could be something about burgundy. It's just stuff going on. And then the opposite. I had a guy who says, no, I don't have any that. But he says I was traveling in France, and we were drinking wine like it was water, and I never had a hangover symptom, and I did it, and I was like, I don't know dude, like I [00:22:45] Andrew Waterhouse: Yeah. Well, there's, there's one answer to some of this, which is if you're on vacation and you don't have to get up early and you're relaxed and you probably don't get as many headaches. [00:22:58] Craig Macmillan: Right. [00:22:59] Andrew Waterhouse: So I think that's a large part of it, especially for Americans visiting Europe. They're on vacation. but I think there is something to the sulfites question. And that is that inexpensive wine often, not always, but often has more bound sulfites. [00:23:18] Craig Macmillan: Yep. [00:23:19] Andrew Waterhouse: And this is probably because those grapes have a little bit more mold on them or a lot more mold. And when they get to the crusher, the winemaker goes, Oh, there's mold on these fruits. So we're going to add sulfites to, to take care of the botrytis, right? [00:23:34] We don't want the fruit to get oxidized and damaged. They had a bunch of sulfites. The consequence of that is that in the finished line, There's a lot more. Bound to SO2, which shows up in the total SO2 number. [00:23:47] You know what it's bound to? [00:23:49] Craig Macmillan: No. [00:23:49] Andrew Waterhouse: It's bound to largely acid aldehyde. [00:23:52] Craig Macmillan: Really? [00:23:53] Oh! Well that would make sense. Yeah, that would make sense. [00:23:56] Andrew Waterhouse: And the, the reason for that is that during the fermentation, the yeast are converting all this sugar the alcohol, but there's an intermediate step which is acetaldehyde. [00:24:06] Craig Macmillan: Right. [00:24:07] Andrew Waterhouse: If you have SO2 floating around, as you would if you'd added a lot of it up front, it binds that acetaldehyde before it gets reduced to ethanol, to alcohol. if you start a fermentation with a high level of added SO2, then you will end up with a wine that has more bound acetaldehyde. And that could be a marker, say, of less expensive wine. [00:24:31] So it's possible that those people are, what they're experiencing is direct ingestion of acetaldehyde, which is being released into the blood and that that's causing them a problem. [00:24:45] Now, I've looked and looked, and I cannot find any data on what's called absorption of acetaldehyde from wine, or from food for that matter. I keep, I'm going to keep looking, [00:24:56] but for some reason or other, this hasn't been subject of a published study, although maybe I just haven't been competent enough to find it. [00:25:05] Craig Macmillan: I doubt that. [00:25:07] Andrew Waterhouse: Well, sometimes these are, you know, they're very specialized and they're indexed in funny ways. And, [00:25:13] You know, and the other thing was, you know, when the study came out, I had all these questions. I was talking to this one reporter and she said, well, I can drink natural wine. [00:25:24] It doesn't give me headaches. And I was like, oh boy, what's this about? [00:25:27] Craig Macmillan: Yeah. [00:25:28] Andrew Waterhouse: But thinking about that further when you make natural wine, you don't add any sulfites or at least you're not supposed to, Right. And consequently in the finished wine, the level of acetaldehyde would have to be very low or else it would smell like sherry. [00:25:41] Craig Macmillan: Right. Right. [00:25:43] Andrew Waterhouse: And yes, granted, many natural wines have funky smells, but they don't by and large smell like sherry. [00:25:49] So it's possible that natural wines have in general, Much less acid aldehyde than conventional one. you know, all these questions have brought up some interesting issues, I think, you know, the industry should be looking into you know, these are these issues like how much acid aldehyde Do we want in our wine and how can we reduce it if we want to reduce it? [00:26:15] I don't think anybody's really looking at that yet. I think that would be a very interesting question to pursue. Oh [00:26:24] Craig Macmillan: you just, you just reminded me of, of something two things that I, I had forgotten about. One I used to teach like enology for babies, enology for dummies thing for the public. I am in no way qualified other than just experience to do that. [00:26:39] But I broke it down in that I do that sugar aldehyde, alcohol arrows, and I'd say, okay, this, this acid aldehyde. Remember this one? This one's coming back. We're going to see this again later. So write this one down. We're going to get to that later. And sure enough, now it's just through the body and, and I think breathalyzers work based on that. [00:27:00] Don't they? It's like density. Something like that. So the aldehyde, they're actually, [00:27:05] I think so. I got to look that up again, but because by the time it gets to your breath, your body's, Processing it, right? Hugely important. Not just that compound, but aldehyde is just kind of a general well, maybe we should all invest in like some kind of, I don't know, AO unit or wine X ray or something at our house. [00:27:21] And then we could get the totals and know before we drink it you know, maybe we could figure out if somebody could come up with a consumer friendly, you know, put it in a vial and shake it and it turns blue. Don't drink it kind of thing. I'm just being silly. I don't know. [00:27:34] Andrew Waterhouse: idea. [00:27:35] Craig Macmillan: You go to different like wine shops and stuff, and there's all kinds of stirs and additives and strainers and funnels and stuff that are supposed to take things out. [00:27:45] And I've always really wanted to see what those things do. They do anything or not, or I don't know. I'd like to try it. Finally, is there one takeaway on this topic, this question to both you, one takeaway you'd like people to know, I [00:27:57] Andrew Waterhouse: well, I think the key thing is that we haven't done any experiments on people yet. [00:28:03] Craig Macmillan: Right. [00:28:04] Andrew Waterhouse: And so what we have here is, I would call it a well founded theory, [00:28:09] Craig Macmillan: Mhmm. [00:28:09] Andrew Waterhouse: I think people shouldn't rush out and start changing the way they drink yet. They might want to try some experiments. But we don't have the final word yet. [00:28:20] Craig Macmillan: Right, right. [00:28:24] Apramita Devi: Same. Yeah. This is just very preliminary study. And we just have a theory out. So we still don't know, like, what happens in the actual body. [00:28:34] Craig Macmillan: Well, I hope that we can do that. [00:28:36] Andrew Waterhouse: We're always looking for support for experiments. If anybody wants to support that, get in touch. [00:28:43] Craig Macmillan: You know, another creative thought that I have when I'm preparing for this is like, you know, , people either get headaches from wine or they don't. If I'm someone who wants to enjoy wine, but gets headaches, I would be really attracted to a product that had a back label if we could make health. statements, which we cannot, that would say now low in quercetin or, you know, headache free, you know, no, we would never get that through TTP, obviously, but but, but, you know, but we went round and round with that on sulfites, you know you know, organic waste, no added sulfites, you know, you can say that. [00:29:14] Andrew Waterhouse: I think it would be possible to perhaps have a declaration on a bottle about the level of quercetin, whether it's high or low. I suppose. I don't know. [00:29:24] One company did get a label through that had resveratrol levels on it, but then TTB stopped approving that. So only one company has that approval. But I think in that case the reason for denying the label is that it is a proxy for health claim. Thank you. [00:29:44] Quercetin, you know, whether it's high or low is really, it's not, it's not making a health claim. We're not claiming that this wine is healthier for you than the other has to do with headaches or not headaches. [00:29:55] And I don't see that as really a health claim. [00:29:58] Craig Macmillan: Well, let's just see how this develops. You never know. Let's face it. I mean, we're talking about nutrition. This is August of 2024, the date for this recording. We're talking about having nutritional labeling on wine. Right? Which I think would be a very interesting nutritional label, quite frankly. [00:30:13] I would, I would love to see that, you know. Zero percent of the RDA of everything, again, at the end of one of my lectures I'd introduce potassium, and at the end I'd say, so how much wine do you have to drink to get your RDA of potassium? You have to drink a gallon and a half of wine a day. So, maybe not a big contributor. Maybe not a big contributor. Where can people find out more about both of you? [00:30:37] Andrew Waterhouse: Well, I think probably the best starting point would be our LinkedIn pages. [00:30:43] Craig Macmillan: And those will be in the show notes. [00:30:45] Andrew Waterhouse: and I do have a website at UC Davis called waterhouse. ucdavis. edu. [00:30:52] Craig Macmillan: And that will be in there as well. What about you, Apremita? [00:30:54] Apramita Devi: For me, LinkedIn page. [00:30:58] And if people want to see about my research or my past research, they can go to my Google Scholar page to [00:31:05] Craig Macmillan: Awesome. Thank you. Well, thanks so much for being here. Our guests today were Andrew Waterhouse, Professor Emeritus in the Department of Viticulture and Enology at UC Davis, and Apramita Devi, a postdoctoral researcher in viticulture and knowledge at UC Davis. Really interesting work. [00:31:21] I'm glad that you folks are doing it. I've been a big fan of you, Dr. Waterhouse, for a long time, and now that I've seen your work, I'm a big fan of you. Apremita. You've done some pretty cool stuff in the last five years. So again, thanks. And thank you for listening to Sustainable Wine Growing with Vineyard team. [00:31:38] Please keep downloading episodes. Please visit the show page. Lots of information there. And we also have a new publication, Understanding Wine Chemistry by Andrew Waterhouse, Gavin Sachs, and David Jeffrey. Is that correct? [00:31:53] Andrew Waterhouse: That's correct. [00:31:55] Craig Macmillan: This is out in the world now. [00:31:57] Andrew Waterhouse: It's just out this month. [00:31:59] Craig Macmillan: That sounds like a must have. [00:32:01] Andrew Waterhouse: I agree. [00:32:03] Craig Macmillan: That sounds like a must have. , I will leave the name out, but there was a very famous book written by a group of folks from CSU Fresno and some collaborators. And I don't have a copy because I bought five copies in my cellar. People stole them every single time. So, this is the same kind of book, folks. [00:32:20] Maybe buy five copies. And just hand them out to give one to your assistant winemaker. Give one to your cellar master and just say, here, these are yours. I'm keeping my copy. Thank you very much. That's, that's really cool. And again, thanks for being on the podcast. [00:32:33] Beth Vukmanic: Thank you for listening today's podcast was brought to you by wonderful laboratories. Wonderful laboratories operates two state of the art high throughput laboratories. He's located in Shaffer, California to support pathogen detection and nutrient analysis. The team provides full service support to customers with field sampling. Custom panels and special projects. They're. Customers include pest control advisors, growers, consultants, seed. Companies, backyard gardeners, ranchers, and more. [00:33:10] Make sure you check out the show notes. To learn more about. Andrew. And Oprah meta. To read a great article about their research. Why do some people get headaches from drinking red wine? [00:33:19] And if you're looking. Looking for. Some more fun wine at trivia to share at holiday parties this season. Listen into sustainable Winegrowing podcast episode. 74, the spirit of wine. [00:33:31] If you liked the show, do. It's a big favor by sharing it with a friend subscribing and leaving us a review. You can find all of the podcasts@vineyardteam.org slash podcast. Podcast. And you can reach us at podcast@vineyardteam.org until next time, this is sustainable. Winegrowing with the vineyard team. [00:33:49]   Nearly perfect transcription by Descript

Send us a texthttps://renegadehealthboss.comIn episode 135  Heather Gray FDN-P  welcomes  Dr.Nathan Bryan. Dr.Nathan Bryan explores how nitric oxide plays a foundational role in optimal health and longevity. Dr. Nathan shares his experience on this powerful molecule's impact on blood flow, sexual health, stem cell activation, and mitochondrial support.  Potential risks and benefits of these compounds and dives into innovative solutions for nitric oxide supplementationIn this podcast you will discover03:35 Heather shares her personal health transformation with nitric oxide.06:16 The science of nitric oxide as a signaling molecule and its connection to aging.08:12 Simplifying the 1980 Nobel Prize-winning discovery of nitric oxide's role in vascular health.10:06 Nitric oxide supports sexual health, brain function, and blood flow.11:15 Unlocking stem cell activity and telomere protection with nitric oxide.12:04 The connection between nitric oxide, mitochondrial health, and detoxification.12:58 Addressing misinformation and contraindications related to nitric oxide.16:05 Inhibition of nitric oxide production can lead to increased inflammation and decreased tissue oxygenation.22:10 Nitric oxide promotes blood flow, mitochondrial function, stem cell mobilization.25:41 The role of oral microbiome and saliva in naturally producing nitric oxide29:21 Nitric oxide revitalizes skin, reduces fine lines, and addresses inflammation by improving blood flow.31:28 Dr.Nathan Bryan shares his diet philosophy, focusing on clean, unprocessed food, homegrown meat, and vegetables.Thank you to our amazing sponsors, without them our podcast would not be possible.  n1o1 Nitric Oxide with Dr.Nathan BryanMHP Vitamins Total Life Changes with Lisa NicholsPlease learn more about our sponsors here.https://renegadehealthboss.com/sponsors/Guest Bio: Dr.Nathan Bryan, a nitric oxide research pioneer, holds a B.Sc. in Biochemistry from UT Austin, a Ph.D. from LSU School of Medicine, and numerous patents for groundbreaking therapies. As Founder and CEO of Bryan Therapeutics, he develops innovative treatments for heart disease, Alzheimer's, and wound healing.To learn more please visit  www.drnathansbryan.comFrom nutrition and stress management to restorative practices, this ebook is your essential companion for a balanced and vibrant life. Perfect for anyone looking to make lasting changes to their health and well-being, this guide empowers you with the knowledge and tools needed to take control of your health naturally. Start your healing journey today FREE mini eBook [Foundations of Health]https://rhbcourses.com/products/free-mini-ebookGet the Foundation of Health Course here. Lose the brain fog, have more energy, and get your gut working right. https://rhbcourses.com/discount/ACTION this link saves you $100 on the course. #NitricOxide #NasalBreathingBenefits #InfraredLightTherapy #chronicillness #warrior #healing #SkincareScience #HealthyEating

This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics: Mechanism of action for IL-31 inhibitor nemolizumab Clinical safety and efficacy data for nemolizumab for treatment of PN Strategies for prescribing IL-31 inhibitors in clinical practice Pearls for patient selection and addressing treatment challenges

On Today's show Shannon gives tips for a great GFCF Thanksgiving and just a great Thanksgiving in general. Today's jargon is Inhibition.

In this episode, Dr. Valentin Fuster discusses groundbreaking research on SGLT2 inhibitors and their impact on heart failure, highlighting the validation of mechanistic proteomic signatures from a major clinical trial. The study reveals how empagliflozin influences over 2,000 proteins, promoting autophagy, enhancing mitochondrial health, and normalizing kidney function, offering new insights into therapeutic strategies for heart failure management.

Show notes at pharmacyjoe.com/episode968. In this episode, I'll discuss linezolid vs clindamycin for toxin inhibition in patients with invasive group A streptococcus infections. The post 968: Linezolid Instead of Clindamycin for Toxin Inhibition appeared first on Pharmacy Joe.

Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.

Show notes at pharmacyjoe.com/episode962. In this episode, I'll discuss the antibiotics that inhibit bacterial toxin production. The post Episode 962: What Antibiotics Are Best At Toxin Inhibition? appeared first on Pharmacy Joe.

Shallow and Jiunta dive into the importance of internet etiquette and its impact on relationships, both personal and professional. The hosts discuss aligning your online presence with real-life values, the significance of reputation, and the consequences of poor online behavior. They explore how authenticity, thoughtful interactions, and a positive digital environment can unlock opportunities and elevate your goals.   PSL1 registration is now live. Learn more at https://www.pre-script.com/psl1   We've got a new sponsor!   Marek Health is a health optimization company that offers advanced blood testing, health coaching, and expert medical oversight. Our services can help you enhance your lifestyle, nutrition, and supplementation to medical treatment and care. https://marekhealth.com/rxd Code RXD   Don't miss the release of our newest educational community - The Pre-Script ® Collective! Join the community today at www.pre-script.com.   For other strength training, health, and injury prevention resources, check out our website, YouTube channel, and Instagram.   For more episodes, subscribe and tune in to our podcast. Also, make sure to sign up to our mailing list at www.pre-script.com to get the first updates on new programming releases.   You can also follow Dr. Jordan Shallow and Dr. Jordan Jiunta on Instagram!   Dr. Jordan Shallow: https://www.instagram.com/the_muscle_doc/ Dr. Jordan Jiunta: https://www.instagram.com/redwiteandjordan/ Aligning Your Online Presence with Your Values and Goals (00:08:14) Consequences of Not Moving Correctly on the Internet (00:19:02) Building Genuine Relationships Online (00:25:17) Respecting the Power of the Internet (00:34:00) High-Quality Interactions (00:38:32) The Power of Inhibition (00:43:40) Moving from Good to Great (00:48:24) Expressing Gratitude and Positivity (00:51:24) Curating Your Digital Environment (01:00:16)